Bladder Overactivity and Post-Botulinum Toxin Telemonitoring
ConditionOveractive Bladder
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Grenoble
About this trial
Prospective, randomized, controlled, single-center study to compare the feasibility of home monitoring for patients receiving intradetrusor botulinum toxin injections with that of the usual hospital-based follow-up.
Eligibility criteria
Qualifiers
Patient with a neurogenic bladder or idiopathic overactive bladder.
Patient treated with intradetrusor botulinum toxin injection as part of their usual care, whether performing spontaneous voiding or self-catheterization.
Patient whose residence allows a home visit by a service provider within the area covered by the AGIR à dom group.
Patient affiliated with the social security system.
Disqualifiers
Persons covered under Articles L1121-5 to L1121-8 of the French Public Health Code (CSP), corresponding to all protected persons: pregnant or postpartum women, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, individuals admitted to a healthcare or social facility for purposes other than research, minors, persons under legal protection, or individuals unable to give consent.
Staff members with a hierarchical relationship with the principal investigator.
Trial design
Treatments tested in this trial
- home care
Treatment groups
112 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov